Figure 5. Anti-TGFβ FOLFIRINOX combination treatment effectively reduces tumor burden in poorly immunogenic mouse tumors.

A) Diagram of experimental protocol for orthotopic 6694c2 mouse model with different treatments. TGFβ blocking antibody and GnP were given as in Figure 2D. FOLFIRINOX (5mg/kg oxaliplatin, 75mg/kg leucovorin, 50mg/kg irinotecan, and 15mg/kg 5-FU) were dosed i.v. at days 3, 6, and 9. B) Mouse body weight was measured. C) Tumor weights at day 15. Results are combined from three independent experiments. D) Mice inoculated with 6694c2 cells were treated with TGFβ blocking antibody or isotype control, +/−GnP, or +/− high dose FOLFIRINOX (5mg/kg oxaliplatin, 75mg/kg leucovorin, 50mg/kg irinotecan, and 75mg/kg 5-FU; dosed i.v. at day 3 and day 6). Spleens were harvested 15 days after inoculation. Spleen neutrophils (CD11b⁺, Gr-1^high, SSC^high) and monocytes (CD11b⁺, Gr-1^mid, SSC^mid) were analyzed by flow cytometry.